肥胖子宫内膜癌患者中GLP-1受体激动剂使用趋势
基于TriNetX美国数据库的回顾性队列研究,纳入2018至2024年BMI≥30的女性,按有无子宫内膜癌诊断分组并进行倾向评分匹配。结果显示两组GLP-1RA使用率均上升,但子宫内膜癌患者始终较低,2024年为7.8%对10.6%(RR 0.73,CI 0.61-0.87),提示肥胖管理存在差距。
要点
- 2018至2024年肥胖女性GLP-1RA使用率整体上升。
- 子宫内膜癌患者GLP-1RA使用率始终低于无癌对照。
- 2024年使用率7.8%对10.6%,RR 0.73(CI 0.61-0.87)。
核心结论
- 尽管肥胖是子宫内膜癌主要危险因素,子宫内膜癌患者接受GLP-1RA的可能性仍低于匹配的无癌患者。
研究设计与样本
- 回顾性队列研究,使用TriNetX美国协作网络2018年1月1日至2024年4月15日的电子健康记录数据。
- 纳入BMI≥30的女性,按有无子宫内膜癌诊断分组,1:1倾向评分匹配人口学、BMI和合并症。
主要发现
- 2018至2024年,两组GLP-1RA使用率均上升。
- 2018年子宫内膜癌组使用率1.0%,无癌组1.2%(RR 0.82,CI 0.60-1.13)。
- 2024年子宫内膜癌组使用率7.8%,无癌组10.6%(RR 0.73,CI 0.61-0.87)。
- BMI≥40亚组中,无癌女性GLP-1RA uptake显著更快。
关键数值与推荐
- 主要结局为GLP-1RA使用;亚组分析限于BMI≥40患者。
临床怎么用
- 提示子宫内膜癌幸存者肥胖管理可能存在不足,需关注GLP-1RA在该人群中的安全性和有效性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most endometrial cancers (EC) are obesity-related; yet, there is little known about utilization of glucagon-like peptide-1 receptor agonist (GLP-1RAs), which are effective weight loss medications, in EC. METHODS: This is a retrospective cohort study using TriNetX US Collaborative Network, a de-identified, longitudinal electronic health record dataset. Female patients were identified from 1/1/2018-4/15/2024 with BMI ≥30 and grouped by presence or absence of EC diagnosis. Patients were followed for two years or up to 4/15/26, whichever came first. These two groups were 1:1 propensity score matched for demographics, BMI, and comorbidities. Patients with prior bariatric surgery or GLP-1RA use were excluded. The primary outcome was GLP-1RA use. Subgroup analysis was conducted among patients with BMI ≥40. RESULT: From 2018 to 2024, GLP-1RAs use in both cohorts increased. However, utilization was consistently lower among patients with EC. In 2018, GLP-1RA use was 1.0% among patients with EC vs. 1.2% among those without EC (RR 0.82, CI 0.60-1.13). By 2024, use increased to 7.8% and 10.6%, respectively (RR 0.73, CI 0.61-0.87). Similar findings were observed among patients with a BMI ≥40, with significantly faster uptake of GLP-1RAs among women without EC. CONCLUSIONS: Patients with EC were less likely to receive GLP-1RAs than matched patients without EC despite obesity being a major risk factor for EC. These findings highlight a potential gap in obesity management among EC survivors and support further investigation of the safety and efficacy of GLP-1RAs in this population.
引用
- Chang HH, Hsieh TYJ, Esselen KM, et al. Trends in use of glucagon-like peptide-1 receptor agonists in obese patients with endometrial cancer. Gynecol Oncol. 2026. PMID: 42966334. doi:10.1016/j.ygyno.2026.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。